BrightGene Stock Hits Day Low of CNY 41.15 Amid Price Pressure

BrightGene Bio-Medical Technology Co., Ltd. experienced a significant decline today, with its stock price dropping by 4.38% to reach an intraday low of CNY 41.15. This performance contrasts sharply with the China Shanghai Composite, which posted a gain of 1.61% on the same day. Over the past week, BrightGene's stock has decreased by 4.32%, and its one-month performance shows a substantial decline of 32.5%. Year-to-date, the stock has fallen by 14.19%, while its one-year performance reflects a decrease of 25.55%. Despite a notable increase of 85.3% over the past three years, the stock's longer-term performance remains under pressure, with a five-year decline of 3.93%. The company's financial metrics indicate challenges, including a high debt-to-equity ratio and a return on equity of just 1.44%. Additionally, BrightGene has reported negative results for the last six consecutive quarters, with net profit declining by 65.94% in the first half of the year. The stock's current valuation, characterized by a price-to-book ratio of 7.35, suggests a premium price relative to its book value.